HIV – Page 2 – Medxy AI

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Clinical Updates HIV/AIDS news Specialties

Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies

By MedXY 07/30/2025

Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.

HIV/AIDS news Specialties

Assessing Antibiotic Use During Pregnancy: Impact on Birth Outcomes in HIV Contexts

By MedXY 07/29/2025

A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.